These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 7926136

  • 1. Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics.
    Espinós JJ, Rodríguez-Espinosa J, Webb SM, Calaf-Alsina J.
    Fertil Steril; 1994 Nov; 62(5):926-31. PubMed ID: 7926136
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [Abstract] [Full Text] [Related]

  • 3. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, Reinwein D, Benker G.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [Abstract] [Full Text] [Related]

  • 4. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL, García-Luna PP, Leal-Cerro A, Cortés A, Trujillo F, Villamil F, Vaquero F, Revuelta M, Astorga R.
    Med Clin (Barc); 1994 Jun 11; 103(2):59-64. PubMed ID: 8051973
    [Abstract] [Full Text] [Related]

  • 5. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
    Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C.
    Gynecol Endocrinol; 1994 Sep 11; 8(3):175-81. PubMed ID: 7847102
    [Abstract] [Full Text] [Related]

  • 6. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I.
    Clin Endocrinol (Oxf); 1990 Aug 11; 33(2):161-9. PubMed ID: 2225475
    [Abstract] [Full Text] [Related]

  • 7. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, de Longueville M, Lancranjan I, Stevenaert A.
    J Clin Endocrinol Metab; 1992 Jul 11; 75(1):275-80. PubMed ID: 1619019
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
    Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F.
    Acta Endocrinol (Copenh); 1991 Nov 11; 125(5):494-501. PubMed ID: 1759539
    [Abstract] [Full Text] [Related]

  • 13. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Nov 11; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 14. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
    Brue T, Lancranjan I, Louvet JP, Dewailly D, Roger P, Jaquet P.
    Fertil Steril; 1992 Jan 11; 57(1):74-80. PubMed ID: 1730334
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T, Arikan E, Tasan E, Hatemi H.
    Intern Med; 2001 Sep 11; 40(9):857-61. PubMed ID: 11579944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May 11; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M, Pagani G, Gianola D, Pagani MD, Salmoiraghi M, Ferrari L, Lancranjan I.
    J Clin Endocrinol Metab; 1986 Jul 11; 63(1):266-8. PubMed ID: 3711262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.